Saleh M, El-Moghazy A, Elgohary A, Saber W, Helmy Y
Vaccines (Basel). 2025; 13(2).
PMID: 40006673
PMC: 11860605.
DOI: 10.3390/vaccines13020126.
Wang J, Cai L, Li N, Luo Z, Ren H, Zhang B
Nanomicro Lett. 2025; 17(1):155.
PMID: 39979495
PMC: 11842722.
DOI: 10.1007/s40820-025-01665-9.
Ullah A, Khan M, Zhang Y, Shafiq M, Ullah M, Abbas A
Int J Nanomedicine. 2025; 20():25-52.
PMID: 39802382
PMC: 11717654.
DOI: 10.2147/IJN.S429279.
Brandi R, Paganelli A, DAmelio R, Giuliani P, Lista F, Salemi S
Vaccines (Basel). 2025; 12(12.
PMID: 39772079
PMC: 11680146.
DOI: 10.3390/vaccines12121418.
Reguzova A, Muller M, Pagallies F, Burri D, Salomon F, Rziha H
NPJ Vaccines. 2024; 9(1):191.
PMID: 39414789
PMC: 11484955.
DOI: 10.1038/s41541-024-00981-2.
mRNA vaccines for infectious diseases - advances, challenges and opportunities.
Pardi N, Krammer F
Nat Rev Drug Discov. 2024; 23(11):838-861.
PMID: 39367276
DOI: 10.1038/s41573-024-01042-y.
Advanced biopolymeric materials and nanosystems for RNA/DNA vaccines: a review.
Pereira L, Tredus J, Cora L, Novacki L, Oliveira G, Vodiani M
Nanomedicine (Lond). 2024; 19(24):2027-2043.
PMID: 39110059
PMC: 11485706.
DOI: 10.1080/17435889.2024.2382077.
A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany).
Kowalzik F, Teschner D, Mesquita M, Jensen C, Schreiner D, Kronfeld K
Vaccine X. 2024; 19:100512.
PMID: 39040887
PMC: 11260592.
DOI: 10.1016/j.jvacx.2024.100512.
A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.
Chavda V, Yadav D, Parmar H, Brahmbhatt R, Patel B, Madhwani K
Curr Top Med Chem. 2024; 24(21):1883-1916.
PMID: 38859776
DOI: 10.2174/0115680266296095240529114058.
Sequence-Optimized mRNA Vaccines Against Infectious Disease.
Rauch S, Lutz J, Muhe J, Kowalczyk A, Schlake T, Heidenreich R
Methods Mol Biol. 2024; 2786:183-203.
PMID: 38814395
DOI: 10.1007/978-1-0716-3770-8_8.
COVID-19 Vaccines: Where Did We Stand at the End of 2023?.
Lundstrom K
Viruses. 2024; 16(2).
PMID: 38399979
PMC: 10893040.
DOI: 10.3390/v16020203.
mRNA-based VP8* nanoparticle vaccines against rotavirus are highly immunogenic in rodents.
Roier S, Prasad V, McNeal M, Lee K, Petsch B, Rauch S
NPJ Vaccines. 2023; 8(1):190.
PMID: 38129390
PMC: 10739717.
DOI: 10.1038/s41541-023-00790-z.
Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice.
Wang Z, Jacobus E, Stirling D, Krumm S, Flight K, Cunliffe R
Mol Ther Nucleic Acids. 2023; 34:102045.
PMID: 37876532
PMC: 10591005.
DOI: 10.1016/j.omtn.2023.102045.
mRNA vaccines in disease prevention and treatment.
Zhang G, Tang T, Chen Y, Huang X, Liang T
Signal Transduct Target Ther. 2023; 8(1):365.
PMID: 37726283
PMC: 10509165.
DOI: 10.1038/s41392-023-01579-1.
Comparative analysis of the effectiveness difference of SARS-COV-2 mRNA vaccine in different populations in the real world: A review.
Cai S, Chang C, Zhang X, Qiao W
Medicine (Baltimore). 2023; 102(34):e34805.
PMID: 37653835
PMC: 10470718.
DOI: 10.1097/MD.0000000000034805.
From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics.
Korzun T, Moses A, Diba P, Sattler A, Taratula O, Sahay G
Pharmaceuticals (Basel). 2023; 16(8).
PMID: 37631003
PMC: 10459564.
DOI: 10.3390/ph16081088.
Modeling the dynamics of COVID-19 with real data from Thailand.
Ibrahim A, Humphries U, Ngiamsunthorn P, Baba I, Qureshi S, Khan A
Sci Rep. 2023; 13(1):13082.
PMID: 37567888
PMC: 10421938.
DOI: 10.1038/s41598-023-39798-9.
An update on vaccine status and the role of nanomedicine against SARS-CoV-2: A narrative review.
Tajnur R, Rezwan R, Aziz A, Islam M
Health Sci Rep. 2023; 6(7):e1377.
PMID: 37404449
PMC: 10315735.
DOI: 10.1002/hsr2.1377.
Potentiating the Cross-Reactive IFN-γ T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine.
Seo Y, Ko A, Shin D, Kim J, Suh Y, Na J
Int J Mol Sci. 2023; 24(11).
PMID: 37298704
PMC: 10253410.
DOI: 10.3390/ijms24119753.
mRNA Vaccine Platform: mRNA Production and Delivery.
Litvinova V, Rudometov A, Karpenko L, Ilyichev A
Russ J Bioorg Chem. 2023; 49(2):220-235.
PMID: 37252004
PMC: 10197051.
DOI: 10.1134/S1068162023020152.